Company / R&D per Share
Monopar Therapeutics R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.62
FY2025
5-year range
$0.10 / $1.88
FY2021-FY2025
Trend
-13.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.59 to $1.62 over the past 2 years.
Based on SEC 10-K filings.
1.62 in FY2025.
Improved from $0.59 to $1.62 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 13.6% year-over-year.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.62 | -13.6% |
| FY2024 | $1.88 | +220.4% |
| FY2023 | $0.59 | +176.8% |
| FY2019 | $0.21 | +110.5% |
| FY2018 | $0.10 | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026